Welcome to our dedicated page for Rapport Therapeutics news (Ticker: RAPP), a resource for investors and traders seeking the latest updates and insights on Rapport Therapeutics stock.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company that regularly issues news about its precision neuroscience programs for neurological and psychiatric disorders. The company’s updates often center on RAP-219, a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator being evaluated in drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.
News for RAPP commonly includes clinical trial milestones, such as Phase 2a results in focal onset seizures, post hoc analyses presented at scientific meetings, and plans for registrational Phase 3 programs. Rapport has reported statistically significant reductions in long episodes and clinical seizures in its Phase 2a FOS trial, along with additional analyses on early onset of action, consistency of response, and improvements in seizure severity measures.
Investors and clinicians following Rapport can also expect announcements about regulatory interactions with the U.S. Food and Drug Administration, including end-of-Phase 2 meetings, clinical hold updates, and investigational new drug (IND)-enabling activities. The company provides updates on its long-acting injectable formulation of RAP-219, its α6β4 nicotinic acetylcholine receptor program for chronic pain and migraine, and other discovery and preclinical efforts in hearing and vestibular disorders.
RAPP news flow further covers financial and corporate developments, such as public offerings of common stock under an effective shelf registration statement, quarterly financial results, and participation in healthcare and investor conferences. For readers tracking Rapport Therapeutics, this news stream offers insight into the progress of its RAP technology platform, the evolution of its epilepsy portfolio, and the status of its broader pipeline in neurology and psychiatry.
Rapport Therapeutics (NASDAQ:RAPP) reported Q2 2025 financial results and provided key business updates. The company's lead program RAP-219 Phase 2a trial for drug-resistant focal onset seizures is fully enrolled with topline results expected in September 2025. Additionally, a Phase 2 trial of RAP-219 in bipolar mania has been initiated.
Financial highlights include a net loss of $26.7 million in Q2 2025, compared to $18.1 million in the prior year. R&D expenses increased to $22.7 million, up from $15.7 million. The company maintains a strong cash position of $260.4 million, expected to fund operations through 2026.
Clinical progress includes positive Phase 1 safety data across 100 healthy volunteers, with no serious adverse events reported. The company is also finalizing plans for a Phase 2a trial in diabetic peripheral neuropathic pain (DPNP).
Rapport Therapeutics (NASDAQ: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in two major healthcare investor conferences in June 2025.
The company will participate in fireside chats at the Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 10:30 a.m. ET, and at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9, 2025, at 10:00 a.m. ET. Both presentations will be accessible via webcast on the company's investor relations website.
Rapport Therapeutics (NASDAQ: RAPP) has announced its first-ever Investor and Analyst Day, scheduled for June 2, 2025, in New York City. The event, to be held at Nasdaq MarketSite from 3:00 to 5:00 p.m. ET, will feature presentations from senior management focusing on the company's clinical programs, particularly the RAP-219 Phase 2a trial in refractory focal epilepsy.
A highlight of the event will be a fireside chat with Dr. Jacqueline A. French, a renowned epilepsy researcher from NYU Langone's Comprehensive Epilepsy Center and principal investigator of the RAP-219 trial. The event will be accessible via live and archived webcasts through the company's investor relations website.
Rapport Therapeutics (NASDAQ: RAPP) reported Q1 2025 financial results and provided key business updates. The company's lead program RAP-219 is progressing with two significant Phase 2a trials: one for refractory focal epilepsy with topline results expected in Q3 2025, and another for bipolar mania starting in Q3 2025. The company reported favorable tolerability across four Phase 1 trials, with PET data showing selective targeting in epilepsy-associated brain regions.
Financial highlights include a Q1 2025 net loss of $24.1 million, with R&D expenses of $19.6 million and G&A expenses of $7.5 million. The company maintains a strong financial position with $285.4 million in cash and investments, expected to fund operations through 2026. Recent appointments include Dr. Jeffrey Sevigny as Chief Medical Officer, and the company plans to host its inaugural Investor and Analyst Day on June 2, 2025.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focusing on small molecule precision medicines for neurological and psychiatric disorders, has announced its participation in three major investor conferences in April and May 2025.
The company will participate in:
- Jones Trading Virtual CNS Symposium - fireside chat on April 29, 2025 (11:00-11:25am ET)
- Citizens JMP 2025 Life Sciences Conference in New York City - fireside chat on May 8, 2025 (1:30-1:55pm ET)
- Mizuho Neuro & Ophthalmology Summit 2025 in New York City - investor meetings on May 21, 2025
Live and archived webcasts of the Jones Trading and Citizens JMP fireside chats will be accessible through the Investors section of Rapport's website.
Rapport Therapeutics (Nasdaq: RAPP) has announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025. The presentations will focus on RAP-219, their clinical-stage AMPA receptor negative allosteric modulator in Phase 2 development for refractory focal epilepsy.
The first poster (#002) will present ROC analysis data showing that a 30% reduction in long episode frequency predicts a clinically meaningful reduction (≥50%) in clinical seizures. The second poster (#003) will demonstrate RAP-219's potent antiseizure effects in preclinical models, with maximal protection achieved at 70% receptor occupancy and 7 ng/mL mean plasma concentration.
Rapport Therapeutics (NASDAQ: RAPP) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its CNS drug development programs. The company's lead candidate RAP-219 showed promising results in PET and MAD-2 trials, demonstrating neuroanatomical specificity and favorable tolerability across 100 healthy subjects with no serious adverse events.
Key financial metrics include a Q4 2024 net loss of $20.0 million (vs $13.5 million in Q4 2023) and full-year net loss of $78.3 million. R&D expenses increased to $17.2 million in Q4 2024, while G&A expenses rose to $6.3 million. The company maintains a strong financial position with $305.3 million in cash and investments, expected to fund operations through 2026.
Notable upcoming milestones include:
- Phase 2a trial topline results in refractory focal epilepsy expected in Q3 2025
- Phase 2a trial initiation in bipolar mania planned for Q3 2025
- Ongoing development plans for diabetic peripheral neuropathic pain treatment
Rapport Therapeutics (Nasdaq: RAPP) has appointed Dr. Jeffrey Sevigny as Chief Medical Officer (CMO), effective immediately. Dr. Sevigny brings over 15 years of leadership experience in translational and clinical drug development, particularly in neuroscience and rare diseases.
Previously serving as CMO at Prevail Therapeutics (an Eli Lilly subsidiary) and SVP of Neuroscience at Eli Lilly, Dr. Sevigny has demonstrated success in building clinical development organizations and achieving corporate milestones including IPO and acquisition processes. His career includes leadership positions at major pharmaceutical companies including Roche, Biogen, Novartis, and Merck.
In his new role, Dr. Sevigny will oversee Rapport's clinical strategy and advance its pipeline of precision medicines, particularly the RAP-219 program, which has shown promising Phase 1 data. His expertise in late-stage clinical trials and regulatory approvals will be important for the company's development of treatments for central nervous system (CNS) disorders.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focused on developing small molecule precision medicines for CNS disorders, has announced its participation in two major investor conferences in March 2025.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference in Boston, featuring a fireside chat on March 4, 2025, from 3:10-3:40pm EST
- The Stifel 2025 Virtual CNS Forum, with a fireside chat scheduled for March 19, 2025, from 10:30-10:55am EST
Investors and interested parties can access live and archived webcasts of both presentations through the Investors section of Rapport's website at investors.rapportrx.com.